Key facts
- QSM Diagnostics’s last known valuation is $5.5M (Dec 2019).
- It has raised $5.6M; the latest was Later Stage VC ($300K) in Mar 2025.
- Notable investors include Creative Destruction Lab, US National Science Foundation, MassChallenge, University of Toronto, Endless Frontier Labs — 21 tracked in total.
- QSM Diagnostics has filed 1 Form D with the SEC, most recently Apr 2020 ($25K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for QSM Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for QSM Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QSM Diagnostics
Operator of a point-of-care veterinary diagnostics development company intended for the rapid identification of bacterial infections. The company offers bacteria testing kits that include a single-use disposable sensor technology used to detect target molecules and monitor and identify infections at the wound site, enabling veterinarians and eventually physicians to improve their diagnoses and treatment plans to provide animal care.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2014
- Employees
- 7
- Website
- qsmdiagnostics.com/
- Ownership
- Privately Held (backing)
QSM Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QSM Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QSM Diagnostics in its N-PORT filings yet. We sweep new filings monthly.